KR101331101B1 - 인자 ｖｉｉ 활성을 갖는 융합 단백질 - Google Patents

인자 ｖｉｉ 활성을 갖는 융합 단백질 Download PDF

Info

Publication number
KR101331101B1
KR101331101B1 KR1020110054573A KR20110054573A KR101331101B1 KR 101331101 B1 KR101331101 B1 KR 101331101B1 KR 1020110054573 A KR1020110054573 A KR 1020110054573A KR 20110054573 A KR20110054573 A KR 20110054573A KR 101331101 B1 KR101331101 B1 KR 101331101B1
Authority
KR
South Korea
Prior art keywords
fvii
fusion protein
linker
seq
transferrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020110054573A
Other languages
English (en)
Korean (ko)
Other versions
KR20110133454A (ko
Inventor
송인영
김훈택
이봉용
박만훈
이호순
임윤정
이지혜
손서연
김민선
Original Assignee
에스케이케미칼주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이케미칼주식회사 filed Critical 에스케이케미칼주식회사
Publication of KR20110133454A publication Critical patent/KR20110133454A/ko
Application granted granted Critical
Publication of KR101331101B1 publication Critical patent/KR101331101B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020110054573A 2010-06-04 2011-06-07 인자 ｖｉｉ 활성을 갖는 융합 단백질 Active KR101331101B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100052719 2010-06-04
KR20100052719 2010-06-04

Publications (2)

Publication Number Publication Date
KR20110133454A KR20110133454A (ko) 2011-12-12
KR101331101B1 true KR101331101B1 (ko) 2013-11-19

Family

ID=45067214

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020110054573A Active KR101331101B1 (ko) 2010-06-04 2011-06-07 인자 ｖｉｉ 활성을 갖는 융합 단백질

Country Status (13)

Country Link
US (2) US9644197B2 (enExample)
EP (1) EP2576625B1 (enExample)
JP (2) JP6143297B2 (enExample)
KR (1) KR101331101B1 (enExample)
CN (2) CN107188970A (enExample)
AU (1) AU2011262494B2 (enExample)
BR (1) BR112012030941A2 (enExample)
CA (1) CA2801223C (enExample)
ES (1) ES2676874T3 (enExample)
MX (1) MX348567B (enExample)
RU (1) RU2585231C2 (enExample)
WO (1) WO2011152694A2 (enExample)
ZA (1) ZA201300066B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015093819A1 (ko) 2013-12-16 2015-06-25 에스케이케미칼주식회사 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011152694A2 (en) 2010-06-04 2011-12-08 Sk Chemicals Co., Ltd. Fusion protein having factor vii activity
EA024507B1 (ru) * 2010-09-28 2016-09-30 Амилин Фармасьютикалс, Ллк Хорошо растворимые лептины
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014129876A1 (ko) 2013-02-25 2014-08-28 에스케이케미칼주식회사 인자 vii을 포함하는 융합 단백질의 분리 및 정제 방법
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
IL317968A (en) 2017-08-18 2025-02-01 Neutrolis Inc Engineered deoxyribonuclease enzymes and their use in medicine
CA3115766A1 (en) 2018-10-08 2020-04-16 Neutrolis, Inc. Engineering of dnase enzymes for manufacturing and therapy
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
CN110218259B (zh) * 2019-06-24 2022-09-16 王跃驹 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用
CN110229237A (zh) * 2019-06-24 2019-09-13 王跃驹 植物生产口服epo与转铁蛋白融合蛋白胶囊的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060130158A1 (en) 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
JP2005508623A (ja) 2001-08-30 2005-04-07 バイオレクシス ファーマシューティカル コーポレイション 改変されたトランスフェリン融合タンパク質
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
CN101519449A (zh) 2001-08-30 2009-09-02 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
BR0304660A (pt) 2002-05-01 2005-06-07 Schering Ag Anticorpos direcionados a fator de tecido como anticoagulantes
US20070072271A1 (en) * 2004-01-07 2007-03-29 Novo Nordisk Healthcare A/G Method for the production of recombinant proteins
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
HUE067285T2 (hu) * 2006-03-24 2024-10-28 Bioverativ Therapeutics Inc PC5 mint IX-es faktor propeptidet feldolgozó enzim
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2009086132A2 (en) 2007-12-20 2009-07-09 University Of Southern California Design of spacers to increase the expression of recombinant fusion proteins
JP2011526303A (ja) 2008-06-27 2011-10-06 デューク ユニバーシティ エラスチン様ペプチドを含む治療剤
US9968309B2 (en) * 2009-12-08 2018-05-15 Koninklijke Philips N.V. Method and a correction system for correcting tracer-uptake measurements
WO2011152694A2 (en) 2010-06-04 2011-12-08 Sk Chemicals Co., Ltd. Fusion protein having factor vii activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060130158A1 (en) 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015093819A1 (ko) 2013-12-16 2015-06-25 에스케이케미칼주식회사 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
US9987339B2 (en) 2013-12-16 2018-06-05 Tiumbio Co., Ltd. Pharmaceutical composition with improved stability containing factor VII fusion protein

Also Published As

Publication number Publication date
ZA201300066B (en) 2014-03-26
WO2011152694A3 (en) 2012-04-19
KR20110133454A (ko) 2011-12-12
US20160194622A1 (en) 2016-07-07
US10696960B2 (en) 2020-06-30
AU2011262494B2 (en) 2016-01-21
WO2011152694A2 (en) 2011-12-08
RU2585231C2 (ru) 2016-05-27
US9644197B2 (en) 2017-05-09
WO2011152694A8 (en) 2013-01-17
CN107188970A (zh) 2017-09-22
JP2017000144A (ja) 2017-01-05
MX2012013807A (es) 2012-12-17
RU2012157301A (ru) 2014-07-20
ES2676874T3 (es) 2018-07-25
CN103068854A (zh) 2013-04-24
BR112012030941A2 (pt) 2017-06-06
JP6422918B2 (ja) 2018-11-14
AU2011262494A2 (en) 2013-08-01
EP2576625B1 (en) 2018-04-25
EP2576625A2 (en) 2013-04-10
JP2013529914A (ja) 2013-07-25
CA2801223A1 (en) 2011-12-08
MX348567B (es) 2017-06-20
CA2801223C (en) 2019-12-03
AU2011262494A1 (en) 2013-01-24
JP6143297B2 (ja) 2017-06-07
EP2576625A4 (en) 2013-11-06
US20130236945A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
KR101331101B1 (ko) 인자 ｖｉｉ 활성을 갖는 융합 단백질
Weimer et al. Prolonged in-vivo half-life of factor VIIa by fusion to albumin
US8828939B2 (en) Modified vitamin K dependent polypeptides
KR101579083B1 (ko) 연장된 반감기를 갖는 변형된 응고 인자 ＶＩＩａ
EP1891091B1 (en) Coagulation factor x polypeptides with modified activation properties
EA012566B1 (ru) Химерный белок, способ его получения и способ лечения заболеваний с применением химерного белка
JP2009533364A (ja) 治療用ポリペプチドのインビボでの回収を増大させる方法
JP5823088B2 (ja) 止血を調節する組成物および方法
EP2631249B1 (en) Fusion protein having factor ix activity
JPH06502986A (ja) ハイブリッドプロテインｃ
CN113646331A (zh) 单链因子viii分子
AU2020242945B2 (en) Factor IX variants and uses thereof in therapy
US20160060612A1 (en) Method of Isolating and Purifying Fusion Protein Comprising Factor VII

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20161020

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170928

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20181113

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20191112

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13